Frontline Pembrolizumab Combo Obtains EU Approval for HER2+ Gastric Cancer

News
Article

Data from the phase 3 KEYNOTE-811 trial highlight a trend towards improved overall survival among patients with HER2-positive, PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma receiving pembrolizumab, trastuzumab, and chemotherapy.

The FDA granted accelerated approval to pembrolizumab, trastuzumab, and chemotherapy as a treatment for locally advanced or metastatic gastric or GEJ carcinoma that is HER2 positive in May 2021.

The FDA granted accelerated approval to pembrolizumab, trastuzumab, and chemotherapy as a treatment for locally advanced or metastatic gastric or GEJ carcinoma that is HER2 positive in May 2021.

The European Commission has approved a combination of pembrolizumab (Keytruda) plus trastuzumab (Herceptin) and fluoropyrimidine- and platinum-based chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic HER2-positive, PD-L1–positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, according to a press release from Merck.1

The approval was supported by findings from the phase 3 KEYNOTE-811 study (NCT03615326) in which investigators reported a statistically significant improvement in progression-free survival and objective response rate with the pembrolizumab combo vs trastuzumab and chemotherapy.2 A trend towards improved overall survival was also observed in the experimental arm, although it was not considered to be statistically significant.

“Patients in the [European Union] EU diagnosed with HER2-positive advanced gastric cancer [have] an aggressive disease associated with a poor prognosis, underscoring the need for additional first-line treatment options for these patients,” Scot Ebbinghaus, MD, vice president of global clinical development at Merck Research Laboratories, said in the press release. “With today’s approval of [pembrolizumab], we’re proud that patients whose tumors express PD-L1 with a combined positive score [of 1 or higher] and health care providers in the EU will have an option that includes immunotherapy for this difficult-to-treat disease.”

The FDA granted accelerated approval to pembrolizumab, trastuzumab, and chemotherapy as a treatment for locally advanced or metastatic gastric or GEJ carcinoma that is HER2 positive in May 2021.3 The regulatory decision was also based on data from the phase 3 KEYNOTE-811 study.

References

  1. European Commission approves KEYTRUDA® (pembrolizumab) plus trastuzumab and chemotherapy as first-line treatment for HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma expressing PD-L1 (CPS ≥1). News release. Merck. August 29, 2023. Accessed August 29, 2023. https://bit.ly/3PhgAeA
  2. KEYTRUDA® (pembrolizumab) plus trastuzumab and chemotherapy met primary endpoint of progression-free survival as first-line treatment in patients With HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. News release. Merck. News release. June 16, 2023. Accessed August 29, 2023. bit.ly/3p903iB
  3. FDA approves Merck’s KEYTRUDA (pembrolizumab) combined with trastuzumab and chemotherapy as first-line treatment in locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma. News release. Merck. May 5, 2021. Accessed August 29, 2023. https://bit.ly/2SjmdOj
Recent Videos
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Related Content
Postoperative complications and mortality after standard or postponed surgery for esophageal cancer after active surveillance were similar in both groups.

Active Surveillance Shows Noninferior OS vs Surgery in Esophageal Cancer

Roman Fabbricatore
April 5th 2025
Article

Postoperative complications and mortality after standard or postponed surgery for esophageal cancer after active surveillance were similar in both groups.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

The pre-specified number of events required to undergo analyses of the secondary end points, including PFS, OS, and DOR, have not been met.

Tovecimig Yields Significant Responses in Advanced Biliary Tract Cancer

Roman Fabbricatore
April 4th 2025
Article

The pre-specified number of events required to undergo analyses of the secondary end points, including PFS, OS, and DOR, have not been met.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

A Staged Approach Offers Benefits Without OS Detriment in Appendix Cancers

A Staged Approach Offers Benefits Without OS Detriment in Appendix Cancers

Tim Cortese
April 2nd 2025
Article

Muhammad Talwa Waheed, MD, found that resection after appendectomy should be prioritized in the treatment of patients with appendiceal cancer.

Data from the phase 3 CheckMate-67T trial support the CHMP’s recommendation for approving subcutaneous nivolumab across various solid tumor indications.

EU’s CHMP Has Positive Opinion for Subcutaneous Nivolumab in Solid Tumors

Russ Conroy
April 1st 2025
Article

Data from the phase 3 CheckMate-67T trial support the CHMP’s recommendation for approving subcutaneous nivolumab across various solid tumor indications.